Mede­or’s cell ther­a­py boosts im­mune tol­er­ance in reg­is­tra­tional tri­al of donor kid­ney re­cip­i­ents

Last year
R&D
Cell/Gene Tx

Mod­er­na looks past post-Covid 'low point' at a fu­ture based on com­bi­na­tion vac­cines, can­cer in­di­ca­tions

Last year
Pharma

No­vo Nordisk is still play­ing catch up as We­govy de­mand rock­ets up­ward

Last year
Pharma
Manufacturing

Up­dat­ed: Eli Lil­ly's Moun­jaro sales hit $1.4B for the quar­ter, but FDA de­ci­sion on Alzheimer's drug is de­layed

Last year
R&D

Sarep­ta’s Duchenne gene ther­a­py gets off to a strong start in sales, as fu­ture lies in lim­bo

Last year
Pharma
Cell/Gene Tx

More peo­ple are us­ing their health ben­e­fits, send­ing in­sur­ers CVS Health and Hu­mana stocks tum­bling

Last year
Health Tech

No­vo Nordisk tem­pers ex­pec­ta­tions for hefty M&A deals as di­a­betes, obe­si­ty sales soar

Last year
Pharma

Ro­bot­ic pill mak­er Rani paus­es pro­grams, cuts head­count to ex­tend cash run­way through 2025

Last year
People
R&D

Sang­amo lays off 160+ staffers, winds down fa­cil­i­ty, punts clin­i­cal pro­grams in dras­tic re­vamp

Last year
People
R&D

Gene ther­a­py biotech Lo­can­abio to shut­ter by year’s end

Last year
People
Startups

JJ Bi­en­aimé is mov­ing out of the C-suite af­ter an 18-year run at Bio­Marin. And you like­ly know his suc­ces­sor

Last year
People

Weight loss start­up Cal­i­brate rais­es $29M as part of pri­vate eq­ui­ty re­struc­tur­ing

Last year
Financing
Health Tech

Am­gen’s win for a Ste­lara in­ter­change­able biosim­i­lar prompts ques­tions about ‘mean­ing­ful com­pe­ti­tion’ un­der IRA

Last year
Pharma
FDA+

No­var­tis scores sixth Cosen­tyx ap­proval from FDA, this time to treat hidradeni­tis sup­pu­ra­ti­va

Last year
Pharma
FDA+

Mer­ck­'s Keytru­da gets bil­iary tract can­cer ap­proval, brings in more pos­i­tive sur­vival da­ta in re­nal car­ci­no­ma

Last year
Pharma

Bi­o­lu­mi­nes­cence Ven­tures makes it of­fi­cial with $477M in as­sets for ear­ly-stage biotech com­pa­nies

Last year
Financing

Q&A: PureTech CEO Daphne Zo­har talks biotech in­ter­ests on Capi­tol Hill

Last year
People
FDA+

Tonix's de­pres­sion fail; Lil­ly ex­er­cis­es op­tion in Sit­ryx deal; Mil­ner stops fight against Ab­cam ac­qui­si­tion

Last year
News Briefing

Si­lence un­veils more PhI da­ta for siR­NA drug in new car­dio­vas­cu­lar race tar­get­ing Lp(a)

Last year
R&D

‘Small mol­e­cules are sexy again’: Gate Bio­science de­buts with $60M and a new way to stop dis­ease-caus­ing pro­teins

Last year
Financing
Startups

Ab­b­Vie seeks Resta­sis fol­low-up with small op­tion fee for Aldeyra’s eye drops, de­spite a po­ten­tial 'im­mi­nen­t' CRL

Last year
Deals
Pharma

Af­ter the ap­plause: New ef­fi­ca­cy ex­pec­ta­tions in urothe­lial can­cer af­ter Pad­cev-Keytru­da da­ta re­veal

Last year
R&D
Pharma

Eli Lil­ly and Boehringer In­gel­heim pay trib­ute to hip-hop an­niver­sary in chron­ic kid­ney dis­ease cam­paign with Rob ...

Last year
Pharma
Marketing

GSK touts Arexvy sales as it dom­i­nates US old­er adult RSV mar­ket, com­pa­ny cuts three ear­ly-stage as­sets

Last year
R&D
Pharma
First page Previous page 252253254255256257258 Next page Last page
A service from the Financial Times